MDT-AP-2286
Med · Medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Med
- cancer_type_detailed
- —
- subtype
- Medulloblastoma
- cancer_type
- Med
- subtype
- Medulloblastoma
- sex
- M
- new_clusters
- C2
- umap1_2d
- 2.685507027
- umap2_2d
- 1.38503454
- umap1_3d
- -0.394450634
- umap2_3d
- -2.179590174
- umap3_3d
- -1.119553735
- dataset
- Med-Taylor
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.540
- MYC_TARGETS_V1+0.400
- E2F_TARGETS+0.330
- KRAS_SIGNALING_DN+0.300
- OXIDATIVE_PHOSPHORYLATION+0.250
- G2M_CHECKPOINT+0.240
- PANCREAS_BETA_CELLS+0.240
- DNA_REPAIR+0.220
- GLYCOLYSIS+0.130
- SPERMATOGENESIS+0.130
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.400
- INTERFERON_GAMMA_RESPONSE-0.380
- NOTCH_SIGNALING-0.380
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.320
- UV_RESPONSE_DN-0.310
- BILE_ACID_METABOLISM-0.270
- MITOTIC_SPINDLE-0.260
- PROTEIN_SECRETION-0.260
- COMPLEMENT-0.250
- TGF_BETA_SIGNALING-0.250
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MDT-AP-1346 | Med | Medulloblastoma | 0.886 |
| 2 | 43c87798-5762-42c1-b7d8-47fc126fc2d3 | — | — | 0.875 |
| 3 | SRR5088864 | — | — | 0.851 |
| 4 | TCGA-E2-A574-01A-11R-A29R-07 | — | E | 0.841 |
| 5 | SRR8518376 | — | E | 0.836 |
| 6 | C3L-00965 | — | cohortSQ2 | 0.834 |
| 7 | BS_JZRM1S3T | medulloblastoma | — | 0.833 |
| 8 | TCGA-39-5037-01A-01R-1443-07 | — | cohortSQ2 | 0.829 |
| 9 | SRR8518345 | — | E | 0.828 |
| 10 | TCGA-YC-A9TC-01A-22R-A39I-07 | — | — | 0.826 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 18 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.540 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.400 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.330 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.300 | Remibrutinib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.250 | Remibrutinib | — uncovered |
| G2M_CHECKPOINT | 0.240 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.240 | Cobimetinib | — uncovered |
| DNA_REPAIR | 0.220 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.130 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.130 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.110 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.110 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.090 | Remibrutinib | — uncovered |
| ADIPOGENESIS | 0.070 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.040 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.030 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.010 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.010 | Temsirolimus | — uncovered |